Skip to main content

Table 4 Univariate analysis of [68Ga]Ga-DOTA-TOC PET/CT variables for PFS after lanreotide therapy

From: Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

Variable

Hazard ratio (95% CI)

p value

Krenning score (2 and 3 vs. 4 )

1.876 (0.713–4.932)

0.202

Tumour-to-liver ratio (TLR) (< 8.1 vs. ≥ 8.1)

3.329 (1.294–8.561)

0.013*

Maximum standardized uptake value (SUVmax) (< 42.94 vs. ≥ 42.94)

2.656 (1.059–6.663)

0.037*

Whole tumour volume (WTV) (≥ 58.9 cm3 vs. < 58.9 cm3)

2.721 (1.100–6.732)

0.030*

Total receptor expression (TRE) (≥ 778.5 vs. < 778.5)

1.837 (0.0.749–4.506)

0.184

  1. *Statistically significant (p < 0.05)